CARRA Welcomes Rachel Myslinski as CEO to Drive Innovation
CARRA Welcomes Rachel Myslinski as New CEO
The Childhood Arthritis and Rheumatology Research Alliance (CARRA) has named Rachel Myslinski, MBA, as its new Chief Executive Officer (CEO). With over two decades of extensive experience in healthcare, Myslinski is set to bring her innovative leadership to the organization.
Experience and Leadership Background
Myslinski has a remarkable background that includes roles in professional medical associations, management consulting, and nonprofit research foundations. Her expertise spans executive leadership, strategic planning, board governance, financial management, philanthropy, and healthcare policy. This diverse experience equips her to effectively steer CARRA in its mission to advance pediatric rheumatology.
Achievements at the Rheumatology Research Foundation
Before joining CARRA, Myslinski served as the Executive Director of the Rheumatology Research Foundation. There, she successfully led the organization’s strategy and operations, promoting significant collaborations within the rheumatology community. A notable accomplishment was her facilitation of a partnership between the Rheumatology Research Foundation and the Lupus Research Alliance. This collaboration aimed to establish the Empowering Lupus Research Partnership, providing support to early career investigators.
Innovative Contributions to Pediatric Rheumatology
Myslinski brings a wealth of knowledge from her previous position as Vice President at the American College of Rheumatology (ACR). At ACR, she was pivotal in the development of the Rheumatology Informatics System for Effectiveness (RISE) Registry. This registry is celebrated as the first and largest electronic health record-enabled registry in the U.S. for rheumatology, playing a crucial role in helping rheumatologists fulfill regulatory requirements and improve patient care.
Vision for CARRA's Future
Expressing her enthusiasm for her new role, Myslinski remarked, "I am looking forward to working closely with the pediatric rheumatology community as part of CARRA's leadership team. CARRA has already brought significant innovation to the field, and I see enormous potential for the organization to enhance its mission of conducting collaborative research aimed at preventing, treating, and curing pediatric rheumatic diseases."
Educational Background and Personal Interests
Rachel Myslinski earned her BA and MBA degrees from Emory University. She also holds a certificate in Public Health from the University of North Carolina, Chapel Hill, and completed a Certificate of Specialization in Leadership and Management from Harvard Business School. Outside of her professional commitments, she enjoys yoga, traveling, and spending quality time with her family in Atlanta.
Transition Period and CARRA's Mission
Myslinski’s official start date at CARRA is set for July 10, 2025. Until then, Larry Hausner will continue to serve as interim CEO. CARRA, a nonprofit organization, is committed to conducting collaborative research that aims to prevent, treat, and cure pediatric rheumatic diseases. Established in 2002 by a dedicated group of physicians, CARRA has expanded to include over 800 members across more than 120 institutions, both in North America and internationally. The organization operates the largest observational multi-center registry for pediatric rheumatic disease and manages two biorepositories located in the US and Canada.
Frequently Asked Questions
Who is the new CEO of CARRA?
The new CEO of CARRA is Rachel Myslinski, who brings extensive experience in the healthcare sector.
What previous role did Rachel Myslinski hold?
Before joining CARRA, Rachel Myslinski was the Executive Director of the Rheumatology Research Foundation.
What is CARRA's mission?
CARRA's mission is to conduct collaborative research to prevent, treat, and cure pediatric rheumatic diseases.
When does Rachel Myslinski start as CEO?
Rachel Myslinski will officially start her role as CEO on July 10, 2025.
What notable contributions has Myslinski made in her career?
Myslinski has played a pivotal role in establishing the RISE Registry, enhancing regulatory compliance for rheumatologists and improving quality of care.
About The Author
Contact Dominic Sanders privately here. Or send an email with ATTN: Dominic Sanders as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.